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1. Introduction  
Malaria remains the most important parasitic disease in the world, causing approximately 
250 million infections annually and one million deaths, mostly in African children. 
International travelers are at risk of developing malaria when visiting endemic regions, 
and account for an estimated 30,000 cases of malaria annually (World Health 
Organization, 2011). The parasite is transmitted by the female Anopheles mosquito and is 
caused by four protozoa of the Plasmodium genus (P. falciparum, P. vivax, P. ovale and P. 
malaria). P. falciparum causes the most significant disease burden with the highest 
morbidity and mortality. In addition to mosquito control and avoidance measures, 
chemoprophylaxis remains a critical component for preventing malaria infection in non-
immune travelers.  
Addressing malaria chemoprophylaxis for the international traveler can be challenging. In 
addition to patient-specific factors, the provider must consider a wide array of other variables, 
such as the predicted risk of malaria associated with the destination, type and duration of 
exposure during the trip as well, as the profile of the drug being prescribed. Seasonal, 
geographic, and climate are among the environmental variables that should be addressed to 
appreciate risk of malaria transmission. There can be upwards of a 200-fold difference in 
relative risk of contracting malaria depending on geographic variables for the international 
traveler, with sub-Saharan Africa conferring the greatest risk (Leder et al., 2004; Freedman, 
2008). The traveler’s accommodations, anticipated understanding and adherence to mosquito 
avoidance and control measures, chemoprophylaxis and access to appropriate medical care 
contribute to the risk of morbidity and mortality associated with malaria. 
Patient-specific variables can also present challenges to the provider. Pregnant, nursing and 
pediatric travelers present unique considerations when determining the most appropriate 
chemoprophylactic regimen. Pregnant patients incur a much higher risk of mortality and 
morbidity from malaria than non-pregnant travelers, and require extensive counselling on 
the risks and benefits of proposed travel to areas at risk of transmission. Emerging parasite 
drug resistance patterns, side-effect profiles, both long and short term, contraindications and 
poor adherence are additional challenges that need to be considered when selecting an 
appropriate antimalarial chemoprophylactic agent. In addition, how to address 
chemoprophylaxis in long-term travelers, generally defined as travel greater than six- 
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months in duration, can be very difficult as consensus guidelines in this population are not 
available (Chen et al., 2006). 
It has been over ten years since the U.S. Food and Drug Administration has approved an 
antimalarial chemoprophylactic drug. Lack of market incentive, increasing difficulty in the 
design and execution of clinical trials, as well as the changing ethical environment after 
Declaration of Helsinki 2000 have contributed to the lag in continued development for the 
malaria chemoprophylaxis indication (Dow et al., 2008). 
2. Education 
Before travel, counseling the individual on the specific risks in the areas they may be visiting 
is an essential part of trip preparation. When counseling the traveler prior to visiting an 
endemic area, they must be made aware of the route of transmission of malaria, associated 
symptoms, variable incubation periods prior to symptom onset, when to seek medical aid, 
and the risks of contracting the disease, including death, especially in high-risk populations. 
They need to be aware that recent immigrants to non-malaria endemic areas returning to 
their home of origin to visit friends and relatives (VFR’s) are at high risk for contracting 
malaria as acquired immunity is not long lasting (Centers for Disease Control and 
Prevention, 2012). Travelers should be counseled on proper personal protective measures 
including mosquito bite avoidance, especially during the peak transmission periods of 
evening and nighttime hours, mechanical and chemical barrier protection, vector control, 
and the appropriate use and importance of chemoprophylaxis.  
Malaria can be effectively treated if suspected and recognized early and appropriate medical 
intervention is made within a timely manner. Time to symptom onset from initial exposure 
can vary, ranging as early as 7 days following a mosquito bite to several months or greater 
following departure from an endemic region. The diagnosis of malaria is a medical 
emergency since time to definitive treatment is a critical factor in determining clinical 
outcome. For these reasons, travelers should be counseled to seek medical care as soon as 
possible if they have any symptoms that may be related to malaria. The clinical presentation 
of malaria consists of a nonspecific, flu-like illness manifested by fever, chills, malaise, 
anorexia and headache. In cases of severe illness, altered mental status, seizures, respiratory 
disease (ARDS) and coma may be present (CDC, 2012). 
Availability of medical care while traveling should be explored prior to travel. There may be 
rare instances where the chemoprophylaxis regimen is suboptimal or the traveler does not 
agree to medically advised chemoprophylaxis. In cases when the traveler develops clinical 
symptoms consistent with malaria and does not have timely access to medical care and 
definitive parasitological diagnosis, presumptive, self-administered therapy may be 
considered (WHO, 2010; CDC, 2012). When prescribing presumptive self-treatment, the 
CDC recommends a consecutive 3-day course of either atovaquone-proquanil or artemether-
lumefantrine. One should never use the same drug for treatment that had been prescribed 
for prophylaxis. It should be stressed to the traveler that even though presumptive 
treatment may be available, they should seek medical care as soon as possible. 
3. Personal protective measures 
Several measures can be taken by the traveler while in endemic areas to reduce the risk of 
mosquito bites, thus reducing the risk of contracting malaria. The Anopheles mosquito only 
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feeds at night, making the hours between dusk and dawn those that the traveler must be 
most vigilant for vector avoidance and mosquito control measures. Staying indoors, 
sleeping in screened-structures, and using mosquito nets during peak feeding times are all 
effective and relatively simple ways to reduce transmission of malaria. Other protective 
measures including clothing that minimizes exposed skin, eliminating mosquito breeding 
sites, and using appropriate repellents/insecticides on skin and clothing, should be 
discussed with the traveler as well (Chen et al., 2006; CDC, 2012).  
A systematic literature review concluded that environmental management programs were 
highly effective at reducing the morbidity and mortality associated with malaria, and if 
educated properly travelers can reduce their risk significantly through these personal and 
environmental protective measures (Keiser et al., 2005). 
Insecticides such as permethrin can be used as a spray to kill mosquitoes on contact, or can 
be used to impregnate clothes and mosquito nets for long-term protection. A 2003 
randomized-controlled trial in sub-Saharan Africa showed a reduction in all-cause child 
mortality by 15-33% with the use of permethrin treated bed nets and curtains, and a 1995 
study of permethrin impregnated uniforms in Columbian soldiers showed a decrease in 
incidence of malaria from 14% to 3% (Phillips-Howard & Nahlen et al., 2003; Soto & Medina 
et  al., 1995), indicating mosquito avoidance and control measures can be highly effective in 
preventing malaria transmission.  
Repellents prevent arthropod bites via alterations to sensorial organs. There are several 
different commercially available repellents including DEET (N,N-diethly-3-methyl-
benzamide), picaridin (2-(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl 
ester), oil of lemon eucalyptus (para-menthane-3,8-diol), and IR3535 (3-[N-butyl-N-acetyl]- 
aminopropionic acid, ethyl ester). The efficacy and duration of repellents vary considerably 
among products and species of mosquito (Zielinski-Gutierrez et al., 2012). Several studies 
have suggested DEET and picaridin to be the most efficacious and long lasting (Fradin & 
Day, 2002; Trigg, 1996; Govere et al., 2000; Badolo et al., 2004). Both DEET and picaridin 
demonstrate efficacy between five and seven hours after application, with variations in 
efficacy and duration of effectiveness related to repellent concentration, humidity, 
temperature, perspiration, exposure to water, and abrasion (Zielinski-Gutierrez et al., 2012). 
There seems to be a ceiling effect with DEET at concentrations above 50%, where higher 
concentrations do not offer additional benefit. 
DEET, at concentrations up to 50%, can be used on children over two months of age. Children 
less than two months should be protected with a child carrier covered with a mosquito net. 
Beyond labeled precautions, the U.S. Environmental Protection Agency (EPA) and CDC do 
not recommend additional warnings for repellents in children > 2 months, pregnant or 
lactating women (Zielinski-Gutierrez et al., 2012). Like physical barriers, repellents and 
insecticides are only effective if used properly and consistently, thus ensuring the traveler is 
aware of proper use before departing is an essential part of pre-trip counseling.  
4. Chemoprophylaxis   
Educating travelers on the clinical indications, as well as proper use and risks of 
chemoprophylaxis is an important part of pre-travel counseling. Patients should be told of 
the options available for the area they are traveling based on CDC recommendations, and 
when clinically indicated, an appropriate chemoprophylaxis should be chosen and 
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prescribed based on the patient’s medical history, tolerability of side effects, compliance, 
and known resistance in the area (Table 1). Resistance to antimalarial drugs is growing, and 
is a major public health concern (WHO, 2010). Resistance of P. falciparum to chloroquine, the 
most widely available and least expensive chemoprophylaxis agent, is now widespread, 
except in a few limited areas of the Caribbean, Central and South America, and a few 
countries in the Middle East. Resistance to mefloquine is spreading and has been confirmed 
in areas of SE Asia including along the borders of Burma and China, Laos and Burma, 
Thailand and Burma, Thailand and Cambodia, and in southern Vietnam (CDC, 2012).  
4.1 Chloroquine 
Chloroquine is a 4-aminoquinoline oral antimalarial agent first introduced in the 1940’s. It 
has good bioavailability, is rapidly absorbed and appreciably concentrated in tissues such as 
the liver, spleen, and to a lesser extent in the CNS (WHO, 2010). Its plasmodicidal activity is 
thought to be related to its interaction with malarial DNA, specifically haem detoxification 
(Castelli et al., 2010; WHO, 2010). Chloroquine is dosed once weekly and is effective against 
the erythrocytic stages of sensitive plasmodium species.  
Chloroquine has long shown its efficacy against malaria, and was a cornerstone of treatment 
until growing resistance became a problem in the 1980’s (Castelli et al., 2010). P. falciparum 
resistance to chloroquine is widespread, thus making it an acceptable choice only in 
chloroquine sensitive areas. There is some evidence of mutations making non-falciparum 
strains resistant, with resistance of P. vivax to chloroquine reported in areas of Papua New 
Guinea, West Papua, Guyana, Vanuatu, Myanmar, Indonesia, and India (WHO, 2010; Kain 
et al., 2001; Davis et al., 2003). 
Chloroquine has a generally mild side effect profile with the most common events being 
nausea, headache, blurred vision, insomnia, and pruritis (Castelli et al., 2010). Serious side 
effects, although rare, include myopathy, hepatitis, hearing loss, Stevens-Johnson Syndrome, 
seizures, and irreversible retinopathy (WHO, 2010). Retinopathy is usually seen after 100g 
cumulative dose, which is equivalent to what a long-term traveler may ingest in 5-6 years of 
weekly dosing (Chen et al., 2006). Chloroquine-induced retinopathy is rare in patients 
taking malaria prophylaxis and is more frequently seen in the higher doses administered for 
the treatment of rheumatoid arthritis (CDC, 2012). In a large (N=2701) trial of peace corps 
volunteers undergoing malaria prophylaxis it was found that chloroquine was better 
tolerated and had fewer serious side effects than mefloquine or doxycycline, however 
prophylaxis in general was not tolerated well with 9% reporting severe events and 23% at 
some point changing their prophylactic medication (Korhonen et al., 2007). 
Chloroquine is considered safe for use in children and pregnancy, however strict adherence 
to weight-based dosing must be adhered to for children since serious adverse events have 
been reported in children receiving as little as 1 gram of chloroquine (Chen et al., 2006). 
While chloroquine is safe for breast-feeding mothers, the infant should receive separate 
prophylaxis as the amount of chloroquine secreted in breast milk is not sufficient for 
protection. 
Chloroquine is available in 500mg tablets, which is equivalent to 300mg chloroquine base. 
Dosing is done weekly starting 2 weeks before travel into an endemic area and for 4 weeks 
after leaving the area. Pediatric dosing is 5mg/kg base, never to exceed adult dosing.  
While generally considered a safe and efficacious drug, the growing resistance to 
chloroquine is making it a choice only available in limited areas of the world. However, 
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because it is one of two current drugs considered safe in pregnant women and children, and 
because it is fairly well tolerated, it will remain a viable choice for prophylaxis if resistance 
patterns are taken into account when prescribing.  
4.2 Primaquine 
Primaquine phosphate is an oral antimalarial agent first approved by the FDA in 1952. The 
mechanism of action is not well understood, but its plasmodicidal activity is thought to be 
related to disruption of the parasitic electron transport chain (Castelli et al., 2010). It has a 
short half-life of approximately seven hours, thus requiring daily dosing. Before the 
approval of primaquine, there was no available treatment of relapsing malaria because anti-
malarial drugs available at the time were only effective against the erythrocytic stages of 
Plasmodium species (Shanks et al., 2001). Primaquine’s approval was important because it is 
effective against both the erythrocytic and exoerythocytic stages of Plasmodium species, 
making it an effective choice for P.vivax, P. ovale, or P. falciparum (WHO, 2010; Shanks, Kain 
et al., 2001). However, it is only FDA-approved for the treatment of vivax malaria, but has 
long been used for treatment off-label for other species and is the drug of choice for terminal 
prophylaxis in travelers at risk for relapsing malaria (Castelli et al., 2010; Hill et al., 2006). 
Multiple clinical trials have shown the efficacy of primaquine against both vivax and 
falciparum malaria (Shanks et al., 2001). In two placebo controlled trials on the island of 
New Guinea it was shown that primaquine had an efficacy of 93 - 95% against P. falciparum 
and 88 - 90% against P. vivax (Baird et al., 2001; Fryauff et al., 1995). In two placebo 
controlled trials done in Columbia good efficacy was also seen, with an overall efficacy of 
89% against P. falciparum and 88% against P. Vivax (Soto et al., 1998, 1999). While good 
efficacy has been seen in the past, there is emerging evidence of increasing resistance to P. 
Vivax strains in some areas of Oceana, South East Asia, and South America (Baird, 2009). 
Primaquine is a well-tolerated medication with the most common side effects being nausea, 
vomiting, and abdominal cramps (Fryauff et al., 1995). It was shown to have better 
tolerability than chloroquine in Irian Jaya transmigrates, and in a retrospective study of 
travelers to Ethiopia it had favorable tolerability compared to mefloquine and doxycycline 
(Schwartz & Regev-Yochay, 1999; Baird et al., 2001). Severe hemolytic anemia can occur in 
patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and should be 
avoided in any patient with this enzymopathy. All patients taking primaquine should be 
evaluated for G6PD deficiency prior to receiving this drug (Hill et al., 2006). 
Off-label dosing recommendations are 30mg base per day for 14 days for terminal 
prophylaxis, and 30mg per day 1-2 days before travel and continued for 7 days after travel 
for prophylaxis (CDC, 2012). It should be taken with food to limit side effects. Dosing for 
children is 0.5 mg/kg base per day. It has been shown safe in studies up to one year with no 
labeled restrictions on duration of use (Fryauff et al., 1995; Chen et al., 2006). Primaquine is 
contraindicated in pregnant women, making prevention or treatment of malaria in areas 
with P.vivax difficult in this population. If used as a primary prophylaxis, it negates the need 
for terminal prophylaxis, however, if another primary chemoprophylaxis is chosen, and 
relapsing malaria is a concern, it makes a good choice for terminal prophylaxis.  
4.3 Mefloquine  
Mefloquine hydrochloride is a methanol-quinoline oral antimalarial agent whose 
mechanism of action is not completely understood, but is thought to be similar to quinine 
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(Castelli et al., 2010). It acts as a blood schizonticide, making it highly effective against the 
erythrocytic stages of Plasmodium species, however it does not have any exoerythrocytic 
activity. Mefloquine has a long half-life, with the average being 21 days, thus only requiring 
once-weekly dosing. Mefloquine is effective against chloroquine resistant Plasmodium 
species, however there are some areas in SE Asia with known mefloquine resistance. Of 
note, mefloquine has been found to have serious neuropsychiatric adverse events, which 
limit its usefulness in certain populations (Castelli et al., 2010; Croft & Garner, 2008). 
Mefloquine efficacy has been shown to be greater than 90% in multiple clinical trials (Kain, 
Shanks et al., 2001), the longest of which was in Peace-Corps volunteers in Africa during the 
early 1990’s. In addition, a review of mefloquine trials found that it did prevent malaria in 
chloroquine resistant areas (Croft & Garner, 2000). Although an effective medication, the 
endemic risk of malaria, current resistance patterns, the drug’s side effect profile and the 
patient’s medical and psychiatric history should be carefully considered before prescribing 
mefloquine (Croft & Garner, 2000). 
The mefloquine label lists many side effects, the most common of which are nausea, 
vomiting, diarrhea, and abdominal pain. However, it also states that mefloquine can cause 
serious mental problems including anxiety, paranoia, hallucinations, and suicidal thoughts. 
These psychiatric problems may lead to prophylaxis discontinuation, and should be 
considered when choosing the appropriate chemoprophylactic regimen. The high rate of 
side effects associated with mefloquine has been shown in several clinical trials including a 
randomized, double blind controlled study of 623 travelers. This study found that 
mefloquine had the highest rate of neuropsychiatric adverse events at 37%, with the highest 
proportion of the events in women. A retrospective study of 4240 patients taking malaria 
prophylaxis completed in 2009 also showed that mefloquine had the highest incidence of 
neuropsychiatric events among antimalarials, and that there were 22 deaths including 5 
suicides associated with normal doses of the drug (Jacquerioz & Croft, 2009). There also 
have been clinical trials showing that mefloquine has a higher rate of discontinuation than 
either placebo (3.3% for mefloquine overall) or atovaquone and proguanil (5% vs. 3.9% of 
atovaquone and proguanil) due to GI upset, dizziness, and neuropsychological events (Kain  
et al., 2001; Hogh et al., 2000). Additionally, Mefloquine has been linked with an increased 
risk of seizures and cardiac arrhythmias, and a 2008 FDA post marketing review associated 
pneumonitis and eosinophilic pneumonia with the use of mefloquine (FDA, 2008). 
Mefloquine is a safe choice for children and women. It is available in 250mg tablets, with the 
dose being 1 pill weekly for adults and for children over 45kg. Mefloquine should be taken 
with food or water. Prophylactic therapy should begin  2 weeks before travel to endemic 
areas, and must continue four weeks after leaving the area. The effectiveness of mefloquine 
against resistant species of plasmodium still makes it a good choice for travelers going to 
chloroquine resistant regions such as Africa, and the fact that it is safe in children and 
pregnant women make it a much more versatile drug. However, the neuropsychiatric 
adverse events and other side effects should be taken into account when choosing it as a 
prophylactic medication.  
4.4 Doxycycline  
Doxycycline is a broad-spectrum antibiotic derived from oxytetracycline that acts on the 30S 
ribosome subunit thus disrupting protein synthesis, and has activity against not only 
bacteria, but several parasitic diseases as well. It has a short half-life, necessitating daily 
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dosing and can be used as a malarial chemoprophylaxis in areas with known chloroquine 
and mefloquine resistance (Kain et al., 2001). It does not have activity against the 
exoerythorcytic stages of malaria making it a less efficacious choice for areas of the world 
with endemic P. vivax and P. ovale. 
Several studies have shown the efficacy of prophylactic doxycycline in the prevention of 
malaria. In a double-blind, placebo controlled study doxycycline had 99% efficacy in the 
prevention of malaria in soldiers in Irian Jaya, Indonesia (Ohrt  et al., 1997). In a separate 
trial investigating the prophylactic efficacy of azithromycin vs. doxycycline in 213 adult 
volunteers in a malaria endemic area it was found that daily doxycycline had an efficacy of 
92.6% vs. 82.7% for daily azithromycin (Andersen et al., 1998). In addition, doxycycline was 
well tolerated in both of these studies.  
While generally well tolerated, the most common side effects of doxycycline are primarily 
gastrointestinal including nausea, vomiting, diarrhea, glossitis, dysphagia, and rare 
instances of esophagitis and esophageal ulceration (Castelli et al., 2010). Doxycycline is a 
photosensitizing agent, and thus care must be taken to prevent over exposure to the sun 
while on this medication. Doxycycline also increases the risk for vaginal candidiasis by 
inhibiting the growth of natural vaginal flora. In a randomized, double-blind, placebo 
controlled trial of 623 non-immune travelers requiring short-term malaria 
chemoprophylaxis, doxycycline demonstrated a comparable side-effect profile to 
atovaquone/proquanal (Schlagenhauf et al., 2003). Importantly however, this study used 
doxycycline monohydrate, the more expensive form of the drug that has a favorable 
gastrointestinal side-effect profile. The findings of this study should not be extrapolated to 
the use of doxycycline hyclate or the non-enteric coated forms of doxycycline, where 
tolerability would likely be less favorable and might affect adherence to this 
chemoprophylactic drug. 
The dosing for adults is 100mg daily. It is contraindicated in children under 8 years of age 
due to the risk of permanent discoloration of the teeth, and in pregnant or breast-feeding 
women due to the risk of toxicity to the fetus/infant (CDC, 2012). The recommended dosing 
for children  8 years of age is 2.2 mg/kg up to 100mg/day (CDC, 2012). Treatment should 
start one to two days before and last for 28 days after leaving an endemic area. Doxycycline 
should be taken with copious water to reduce the risk of esophagitis and may be taken with 
food to reduce GI side effects, although caution should be taken to avoid concomitant 
administration of antacids, magnesium salts, or bismuth subsalicylate as these may decrease 
intestinal absorption. The traveler should remain upright for at least 30 minutes following 
administration to reduce the risk of esophageal irritation or ulceration.  
4.5 Atovaquone and proguanil hydrochloride 
Atovaquone and proguanil is a combination antimalarial that works by inhibiting parasite 
mitochondrial electron transport and parasitic DNA synthesis by inhibiting dihydrofolate 
reductase. Proguanil significantly enhances the ability of atovaquone to inhibit parasitic 
mitochondrial electron transport (Kain et al., 2001; McKeage & Scott, 2003; Srivastava & 
Vaidya, 1999). 
Atovaquone/proguanil is a once daily medication that is effective against both the 
erythrocytic and exoerythorcytic stages of malaria making this an acceptable choice not only 
for P. falciprum, but also P. vivax and P. ovale, both of which have hepatic life cycles. The 
efficacy of atovaquone as a causal prophylaxis was seen in a small volunteer challenge study 
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in which it was shown that parasites were eliminated prior to the establishment of 
erythrocytic infection, thus supporting causal efficacy (Shapiro et al., 1999). 
Atovaquone/proquanal has demonstrated efficacy for malaria prophylaxis in areas with 
predominantly P. vivax (Soto et al., 2006). 
Atovaquone/proguanil’s suppressive prophylaxis effectiveness has been shown in several 
clinical trials, three of which were among semi-immune populations in Gabon, Kenya, and 
Zambia and conducted as double-blinded, randomized, and placebo controlled trials, where 
overall efficacy of 98% in preventing malaria was observed in this population (Lell et al., 
1998; Shanks et al., 1998; Sukwa et al., 1999; Kain et al., 2001). In two other large studies, in 
which non-immune travelers to malaria endemic regions were randomized to receive 
atovaquone/proguanil, mefloquine, or chloroquine plus proguanil, none of the patients in 
the atovaquone/proguanil arms who completed the study developed malaria (Hogh et al., 
2000; Overbosch et al., 2001). It was also shown to be 100% effective against P. falciparum in 
non-immune Columbian soldiers (Soto et al., 2006). In a study of non-immune Indonesian 
immigrants, atovaquone/proguanil was 93% effective at preventing P. falciparum and 84% 
effective at preventing P.vivax (Ling et al., 2002).  
The causal prophylactic activity of atovaquone/proguanil results in required dosing for 
only 1-week post exposure vs. up to 4 weeks with antimalarials that only have activity 
against the erythrocytic stage of the parasite, which may contribute to better adherence by 
travelers than some other malaria prophylaxis (Kain et al., 2001). In addition, the 
discontinuation rate due to side effects of the medication was found to be lower in 
atovaquone/proguanil then either mefloquine or chloroquine/proguanil (1.2%, vs. 5.0% and 
0.2% vs. 2.0%, respectively) (Hogh et al., 2000; Overbosch et al., 2001). In a randomized 
control study, atovaquone/proguanil had a relatively low incidence of reported side effects 
compared to other available chemoprophylactic agents (Schlagenhauf et al., 2003). The most 
serious side effects of atovaquone/proguanil, although rare, include Steven-Johnson 
Syndrome, and a transient elevation of liver enzymes, while the most common were 
headache, abdominal pain, cough, diarrhea, and myalgias (McKeage & Scott, 2003). 
Atovaquone/proguanil tablets are available in two formulations, adult and pediatric with 
the adult tablet containing 250mg of atovaquone and 100mg of proguanil, and the pediatric 
tablet containing 62.5 mg and 25mg of atovaquone and proguanil, respectively. Adult 
dosing is 1 adult tablet daily for 1-2 days before travel into an endemic area, daily 
throughout the stay, and then for 7 days once out of the endemic area. Dosing in the 
pediatric population is the same as for adults, except the number of pediatric tablets given 
daily is weight based. Atovaquone is highly a lipophilic compound in which the rate and 
extent of absorption is increased when taken with dietary fat, thus atovaquone/proguanil 
should be taken with food or a milky drink. While the safety of atovaquone/proguanil in 
the adult and pediatric populations has been shown through clinical trials, the safety during 
pregnancy is unknown and is contraindicated in this population. In addition, this 
medication should be avoided in mother’s breastfeeding infants under 5kg and should not 
be used in patients with severe renal impairment (creatinine clearance < 30 ml/min). 
While there are some case reports of resistance, in general atovaquone/proguanil is an 
efficacious, well-tolerated medication that should be considered first line in chloroquine and 
mefloquine resistant areas. The cost is higher than with other antimalarial 
chemoprophylactic drugs, which may limit its use in certain circumstances. Once 
atovaquone/proguanil becomes generic, this drug may be a more affordable option for 
malaria chemoprophylaxis in the future.  
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Table 1. Malaria Prophylaxis Options 
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5. Special populations 
Children and pregnant women are at the highest risk for severe malaria when traveling to 
endemic areas and increased vigilance should be taken when dealing with these 
populations. It should be recommend that travel to endemic areas with a risk of 
transmission be avoided by these populations if possible, however if patients insist, the 
provider should stress that the traveler or the parents of the traveler insure that both 
personnel protective measures and chemoprophylaxis are strictly adhered to. 
5.1 Pregnancy 
Contracting malaria while pregnant puts the mother at an increased risk for adverse 
outcomes. Malaria infection during pregnancy has been associated with premature labor, 
abortion and stillbirth. The traveler should be counseled that the diagnosis of malaria in 
pregnancy may be difficult due to relatively low parasitemia at clinical presentation. A very 
high degree of suspicion should be taken when a pregnant women presents with fever in an 
endemic area, as missing the diagnosis could have grave consequences (McGready et al., 
2004). Appropriate precautions should be followed including mosquito avoidance and 
control measures discussed previously as well as chemoprophylaxis when clinically 
indicated. Reviewing label-specific information and current CDC recommendations should 
be adhered to. There are no published data indicating elevated risks with the use of DEET in 
pregnant or lactating women, and current U.S. Environmental Protection Agency and CDC 
sources do not advise additional precautions for using FDA-approved insect repellants in 
this population (Koren et al., 2003; Zielinski-Gutierrez et al., 2012). Chemoprophylaxis in 
pregnancy is limited, as both doxycycline and primaquine are contraindicated, and 
atovoquone/proguanil is not currently recommended due to lack of safety data from clinical 
studies. Medications considered safe during pregnancy include chloroquine and mefloquine. 
While data in the past have only recommended mefloquine in the last half of pregnancy, 
current recommendations state that there is no evidence of adverse outcome if taken in any of 
the three trimesters of pregnancy when no other option is available (CDC, 2012). 
5.2 Children  
Children are at risk of malaria and the associated complications while traveling to endemic 
areas, and should have the same personal protective measures as adults. DEET has been 
shown to be safe and effective and is recommended for use by both the CDC and the 
American Academy of Pediatrics (AAP) for all children over 2 months of age at 
concentrations between 10-30% based on duration of protection required (Koren et al., 2003; 
AAP, 2009, 2011; CDC, 2012). Chemoprophylaxis for children is not as restricted as for 
pregnant women, with contraindications including doxycyline usage in children under 8 
and primaquine usage in G6PD deficient patients. Atovaquone/proguanil is FDA approved 
for children greater than 11kg but recommended for off-label use by the CDC and AAP for 
children >5 kg. Mefloquine is only FDA approved for children > 5 kg and older than 6 
months of age, but when necessary recommend off-label for children < 5kg and any age 
(AAP, 2009; CDC, 2012). Parents of very young infants should be counseled to avoid areas 
endemic for malaria given the risk of severe disease in this population. Adherence to 
personal protective measures and chemoprophylaxis if often poor in children, and thus it 
must be stressed to the traveling parent the importance of these precautions.  
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6. Existing challenges and future possibilities 
As outlined in this chapter, there are only five available options for malaria 
chemoprophylaxis in the United States, one of which, primaquine, is not FDA approved for 
this indication. Emerging resistance, traveler intolerance, non-adherence, side effects and 
contraindications to existing options warrant development of newer agents for future 
chemoprophylactic use. 
Resistance to existing drugs is well documented. Wide spread chloroquine resistance has 
led to the use of this drug in only very limited areas of the world, and mefloquine 
resistance continues to emerge. Doxycycline resistance has not been established and there 
is no well accepted definition or validated approach to measuring primaquine resistance 
(Baird, 2009). Primaquine tolerant or refractory strains of P. vivax have been well 
described, notably the Chesson strain from New Guinea (Collins & Jeffery, 1996). As 
resistance continues to emerge among existing options for the prevention of malaria, the 
importance of developing new and effective chemoprophylactic drugs for the 
international traveler becomes critical. 
There are very few candidates currently being developed for malaria chemoprophylaxis, 
and the last FDA approval for this indication, atovoquone/proquanil, was over ten years 
ago in 2000. Doxycycline and mefloquine received FDA approval for malaria 
chemoprophylaxis in the preceding 11 years prior to the atovoquone/proquanil approval. 
The current lack of development of drugs for this indication is unprecedented and is cause 
for great concern.  
Many reasons have been postulated for the lack of candidates in the developmental pipeline 
for the chemoprophylaxis indication. Obvious barriers are the lack of market incentive for 
this indication, although it is clear that the number of international non-immune travelers 
visiting endemic malarious regions has increased substantially in the last few decades, with 
case fatality rates ranging from 1-3% for falciparum malaria (Chen & Keystone, 2005). One 
challenge that has been attributed to stalled development in this area is the 5th Amendment 
to the Declaration of Helsinki (DH2000). First adopted by the World Medical Association 
(WMA) in 1964, the Declaration of Helsinki was an attempt to formally identify core ethical 
principles and guidelines for physicians and others involved in the design, execution and 
oversight of clinical research (Carlson et al., 2004). Principles relating to the use of placebo in 
clinical trials, post-trial access to investigational drugs, and social benefit as defined in 
DH2000, have presented challenges to existing models and development strategies for 
antimalarial chemoprophylactic drugs. Strategies to address these challenges in clinical 
development have been proposed (Dow et al., 2008).  
Azithromycin, piperaquine, and tafenoquine have all been suggested as possible future 
chemoprophylactic drugs (Dow et al., 2008). Azithromycin has shown some promise, 
however future study is needed with combination agents to clarify its role for this indication 
(Chen & Keystone, 2005).  
Tafenoquine, an 8-aminquinolone is a synthetic analogue of primaquine. First developed by 
the Walter Reed Army Institute of Research as WR238605 or etaquine, tafenoquine has a 
very long elimination half-life of approximately 14 days allowing weekly dosing. This novel 
compound shows promise for causal chemoprophylaxis against P. falciparum and P. vivax, as 
well as radical cure of P. vivax. It has been shown in rhesus monkeys to have 10x higher 
potency than primaquine for causal prophylaxis, and has demonstrated greater activity 
against blood and liver-stage parasites in vitro. (Cooper et al., 1994; Shanks et al., 2001). 
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In phase I studies of tafenoquine the drug is well tolerated with single doses up to 600mg 
and with chronic dosing (6 months) at 200mg weekly following a load of 200mg daily for 3 
days (Brueckner et al., 1998; Leary et al., 2009) with no dose-limiting adverse events. The 
most common side effects observed are gastrointestinal, including heartburn, nausea and 
gas, usually associated with higher (>200mg) dosing. The most significant toxicity 
associated with tafenoquine is the potential to induce hemolysis in G6PD deficient 
individuals and methemoglobinemia (Crockett & Kain, 2007). GlaxoSmithKline, in 
partnership with Medicines for Malaria Venture, are undertaking an ascending-dose safety 
study of tafenoquine in G6PD heterozygous patients to identify the maximum safe dose in 
this population (MMV, 2011).  
There have been several placebo-controlled trials evaluating tafenoquine as a causal 
antimalarial chemoprophylactic drug. In a study of non and semi-immune Thai soldiers, 
tafenoquine was administered monthly at 400mg, following a 1200mg loading dose (given 
as 400mg/day for 3 days) for a total of 6 months and demonstrated a protective efficacy 96% 
for P. vivax and 100% for multidrug-resistant P. falciparum (Walsh et al., 2004).  
In a dose ranging prophylactic trial of tafenoquine to prevent P. falciparum in Gabon semi-
immunes, which included children, doses of 25mg, 50mg, 100mg or 200mg/day for three 
consecutive days were tested. Tafenoquine was given one week following treatment with 
halofantrine. Subjects were actively followed for positive blood smears at day 56 and day 77 
following tafenoquine dosing. Notwithstanding the 25mg dose, which uniformly failed, 
tafenoquine demonstrated 100% protective efficacy (PE) at all doses of 50mg or greater at 
day 56 and had PE of 80%, 93% and 100% at day 77 for doses of 50mg, 100mg and 200mg, 
respectively (Lell et al., 2000). 
In a 13-week prophylactic trial in Kenyan semi-immune adults, tafenoquine was evaluated 
at weekly doses of 200mg and 400mg followed by a 600mg and 1200mg 3-day load, 
respectively. A third group consisted of a loading dose (1200mg load), followed by weekly 
placebo and a fourth group received placebo only throughout the 13-week period. The 
200mg and 400mg weekly doses demonstrated PE of 91% and 93%, respectively. The 
loading dose only group had a PE of 80% (Shanks et al., 2001). 
A large randomized, non-placebo controlled trial of non-immune Australian soldiers 
evaluated tafenoquine, dosed at 200mg weekly for 6 months following a loading dose 
(200mg/day for 3 days) while deployed to East Timor. Study participants were randomized 
3:1 to receive either tafenoquine (n=492) or mefloquine (n=162) throughout their 
deployment. Although treatment-emergent adverse events were similar between the two 
groups and tafenoquine was well-tolerated during the study, there were no cases of malaria 
in any group. Exposure to malaria could not be assessed and therefore efficacy was not 
established (Nasveld et al., 2010).  
In a subset of subjects (n=74) in the East Timor study who received tafenoquine, detailed 
safety assessments were conducted which detected vortex keratopathy. This finding had no 
effect on visual acuity and was fully resolved within one year following cessation of therapy 
(Nasveld et al., 2010). More extensive clinical ophthalmic evaluation of tafenoquine in a 
subsequent phase 1 safety trial further supports the vortex keratopathy seen with 
tafenoquine is not clinically significant (Leary et al., 2009).  
Tafenoquine shows promise as a causal prophylactic drug and is currently being developed 
for a radical cure indication for P. vivax through a joint collaboration between 
GlaxoSmithKline and Medicines for Malaria Venture (MMV, 2011).  
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7. Conclusion 
Addressing malaria chemoprophylaxis for the international traveler can be challenging and 
should be done within the context of a comprehensive medical evaluation well before 
visiting the endemic region. Malaria is a life-threatening illness and requires a 
multidimensional, individually tailored approach to ensure the most appropriate measures, 
including non-drug strategies, are taken to prevent infection if the traveler is exposed. 
Existing chemoprophylactic drugs offer effective options for the international traveler, 
however emerging resistance, side effect profiles and contraindications limit use in many 
circumstances. Future effort is needed to identify and develop new effective and safe 
options for malaria chemoprophylaxis. 
The views expressed in this chapter are those of the authors and do not necessarily reflect 
the official policy or position of the Department of the Navy, Army or Air Force, the 
Department of Defense, nor the U.S. Government 
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